Tetrahedron Letters 50 (2009) 5906–5909

Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet

A facile entry into a novel class of dispiroheterocyclic framework through 1,3-dipolarcycloaddition of azomethine ylides with 3-arylidene-4-chromanones as dipolarophiles

T. Augustine [a], Charles C. Kanakam [a], Scholastica Mary Vithiya [b], V. Ramkumar [c,*]

[a] Postgraduate and Research Department of Chemistry, Presidency College, Chennai 600 005, India
[b] Post graduate and Research Department of Chemistry, Auxilium College, Vellore 632 006, India
[c] Department of Chemistry, Indian Institute of Technology, Chennai 600 036, India

ARTICLE INFO

Article history:
Received 25 April 2009
Revised 1 August 2009
Accepted 7 August 2009
Available online 12 August 2009

Keywords:
Chromanones
Azomethine ylides
Dispiroheterocycle
1,3-Dipolar cycloaddition

ABSTRACT

The cycloaddition reaction of azomethine ylides, generated through decarboxylation, with (*E*)-3-arylidene-4-chromanones as dipolarophiles has been investigated. A high degree of regioselectivity has been observed in the synthesis of a new class of functionalized dispiroheterocyclic compounds bearing chromanone and acenaphthenequinone framework. The structures were established by spectroscopic techniques as well as single crystal X-ray analysis.

Spiroheterocycles represent an important class of naturally occurring substances characterized by their highly pronounced biological activities.[1–3] Intermolecular 1,3-dipolar addition reactions are considered as one of the most useful processes for the construction of five-membered ring containing the pyrrolidine structural unit.[4,5] This method is widely used for the synthesis of natural products such as alkaloids and pharmacologically important compounds.[6] 1,3-Dipolar cycloaddition provides a way for the synthesis of many dispiroheterocyclic systems through the cycloaddition reaction of azomethine ylides with the definite dipolarophiles.

Pyrrolidine and oxindole alkaloids[7] constitute another class of compounds with significant biological activity which are normally found in rhyncotylline, corynoxeine, nitraphylline, vincatine, horsifiline, etc. Highly substituted pyrrolidines have attracted much interest as they contribute to the central structural element of many alkaloids and pharmacologically active compounds.[8,9] Although highly substituted spiropyrrolidines are known, there seems to be no report on the synthesis of dispiroheterocycles using acenaphthenequinone and chromanone moiety. In pursuit of our research on the synthesis of novel dispiropyrrolidinyl derivatives (**4a–g**), we herein report the 1,3-dipolar cycloaddition reactions of (*E*)-3-arylidene-4-chromanones (**3**) with the azomethine ylides generated from acenaphthenequinone (**1**) and sarcosine (**2**) through decarboxylation method.

Refluxing a solution of (*E*)-3-benzylidenechroman-4-one (**3**) in boiling aqueous methanol with acenaphthenequinone (**1**) and sarcosine (**2**) afforded 1-*N*-methyl-spiro[2.2′] acenaphthen-1′one-spiro[3.3″](chroman-4″-one)-4-aryl pyrrolidine (**4**) (Scheme 1, Table 1). The reaction gave a single product in all cases as evidenced by thin layer chromatography (TLC). The reaction afforded a series of novel spiro derivatives (**4a–g**)[15–21] through regioselective cycloaddition of azomethine ylides with the exocyclic double bond of 3-arylidene-chroman-4-ones (**3**) in all cases. No trace of the other regioisomer (**5a–g**) was detected. The cycloaddition proceeded smoothly to afford the *syn-endo* cycloadduct.[10] The regio and stereochemical outcome of the cycloaddition was determined by spectrochemical and single crystal X-ray analysis.[11]

The IR spectral analysis of 4 showed two carbonyl peaks at 1690 cm^{-1} and 1718 cm^{-1} which correspond to the chromanone and acenaphthenequinone ring carbonyls, respectively. The ^1H NMR spectrum of the cycloadduct **4**, exhibited a singlet at δ 2.09, which corresponds to N–CH_3 protons. A triplet at δ 4.98 corresponds to benzylic proton. The regiochemical outcome of the azomethine ylide cycloaddition with conformationally restricted *S-cis* enones, 3-arylidenechroman-4-ones (**3**) is probably attributed to the involvement of the antiylide[12] in the transition state, where the *exo* orientation of the dipolarophile to *W*-periphery of the ylide prevents the formation of the *syn* ylide which is not observed due

* Corresponding author. Tel.: +91 044 22575244.
E-mail address: vramkumar@iitm.ac.in (V. Ramkumar).

0040-4039/$ - see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2009.08.010



Scheme 1.

to the unfavorable steric repulsions between the carbonyl oxygen of acenaphthenequinone ring and chroman-4-one ring systems.[13] Further the NOE studies show the nonbonded interactions between the conformationally nearer protons in the molecules, which is further confirmed in the crystal structure of the compound.[14]

Further, the regiochemistry of the cycloadduct **4** was established by the ^{1}H NMR spectrum where a doublet at δ 4.56 corresponds to aryloxymethyl protons and a doublet at δ 3.28 corresponds to N–CH_2 proton. Also the ^{13}C NMR showed two signals at δ 62.00 and δ 71.47 due to the spiro carbon atoms and peaks at δ 192.02 and δ 206.31 due to the chromanone and acenaphthenequinone ring carbonyls, respectively. The mass spectrum of the compound showed a peak at *m/z* 474.02 (M^+), which corresponds to the molecular weight of the compound. Identical results were observed for the other derivatives irrespective of the nature of the substituent present in the arylidene moiety.

Table 1
Synthesis of 1-*N*-methyl-spiro[2.2′]acenaphthen-1′-one-spiro[3.3″](chroman-4″-one)-4-aryl pyrrolidines (**4a**–**g**)[15–21] via Scheme 1

Compound	R_1	R_2	R_3
4a	H	H	OCH_3
4b	CH_3	OCH_3	CH_3
4c	H	OCH_3	CH_3
4d	CH_3	OC_2H_5	CH_3
4e	OCH_3	OC_2H_5	CH_3
4f	OCH_3	OCH_3	CH=CH (CH_3)
4g	CH_3	H	OCH_3

As part of our ongoing research, another series of novel spiropyrrolizines (**7a–f**)[22–27] were synthesized (Scheme 2, Table 2), which are structurally similar to compounds **4a**–**g** but differ in the *N*-methyl group where a pyrrolizine moiety replaces the *N*-methyl group.





Scheme 2.

Table 2
Synthesis of spiro[2.2′]acenaphthen-1′-onespiro[3.3″]-4-arylhexahydro pyrrolizine (**7a–f**)[22–27] via Scheme 2

Compound	R_1	R_2	R_3
7a	H	H	OCH_3
7b	H	OCH_3	CH_3
7c	OCH_3	OCH_3	CH_3
7d	CH_3	OCH_3	CH_3
7e	OCH_3	OC_2H_5	OCH_3
7f	CH_3	H	OCH_3

Refluxing a solution of (*E*)-3-benzylidenechroman-4-one (**3**) in boiling aqueous methanol with acenaphthenequinone (**1**) and L-proline (**6**) afforded spiro [2.2′] acenaphthen-1′-onespiro[3.3″]-4-aryl hexahydro pyrrolizine. The reaction gave a single product in all cases as evidenced by thin layer chromatography (TLC). The reaction afforded a series of novel spiro derivatives through regioselective cycloaddition of azomethine ylide with the exocyclic double bond of 3-arylidenechroman-4-ones (**3**) in all cases. No trace of the other regioisomer was detected.

The IR spectral analysis of **7** showed two carbonyl peaks at 1690 cm^{-1} and 1710 cm^{-1}, which correspond to the chromanone and acenaphthenequinone ring carbonyls. The ^1H NMR spectrum of the cycloadduct **7** exhibited a doublet at δ 4.63, which corresponds to the aryloxy methyl proton. This is infact a doublet of doublet due to the two protons that are diastereotropic in nature. A doublet at δ 4.87 corresponds to the benzylic proton. A triplet at δ 3.41 corresponds to N–CH_2 proton. A quartet at δ 3.32 corresponds to N–CH proton. ^{13}C NMR spectrum of **7** adds conclusive support for the proposed structure. The ^{13}C NMR spectra of **7** exhibit the presence of two spiro carbons at δ 66.70 and δ 71.65 and chromanone and acenaphthenequinone ring carbonyls at δ 194.35 and δ 205.55. The signals at δ 55.79 and δ 48.14 indicate the presence of benzylic and N–CH_2 carbon. The mass spectrum of the compound showed a peak at *m/z* 500.18 (M^+), which corresponds to the molecular weight of the compound. Identical results were observed for the other derivatives irrespective of the nature of the substituent present in the arylidene ring.

In conclusion, we synthesized several novel spiropyrrolidines and spiropyrrolizines using 1,3-dipolar cycloaddition of azomethine ylides with 3-arylidene-4-chromanones. In both cases, the azomethine ylide was generated through decarboxylative route and these studies showed that, in most cases, the azomethine cycloadditions are highly regioselective, giving good yields of novel dispiroheterocycles.

References and notes

1. Longeon, A.; Guyot, M.; Vacelet, J. *Experentia* **1990**, *46*, 548–556.
2. Kobayashi, J.; Tisuda, M.; Agemi, K.; Shigemori, H.; Ishibashi, M.; Sasaki, T.; Mikami, Y. *Tetrahedron* **1991**, *47*, 6617.
3. James, D. M.; Kunze, H. B.; Faulkner, D. J. *J. Nat. Prod.* **1991**, *54*, 1137.
4. Lown, J. W.. In *1,3-Dipolar Cycloaddition Chemistry*; Padwa, A., Ed.; Wiley: New York, 1984; Vol. 1, p 653.

5. Tsuge, O.; Kanemasa, S.. In *Advances in Heterocyclic Chemistry*; Katritzky, A. R., Ed.; Academic: San Diego, 1989; Vol. 45, p 232.
6. Williams, R. M.; Fegley, G. J. *Tetrahedron Lett.* **1992**, *33*, 6755.
7. Garner, P. P.; Cox, P. B.; Klippenstein, S. J. *J. Org. Chem.* **1994**, *59*, 6570.
8. Luibineau, A.; Bouchain, G.; Queneau, Y. *J. Chem. Soc., Perkin Trans 1* **1995**, 2433.
9. Deshong, P.; Leginus, J. M. *J. Am. Chem. Soc.* **1983**, *105*, 1686.
10. Fokas, D.; Ryan, W. J.; Casebier, D. S.; Coffen, D. *Tetrahedron Lett.* **1998**, *39*, 2235.
11. Augustine, T.; Ramkumar, V.; Arul, A. S.; Kanakam, C. C. *Acta Crystallogr., Sect. E* **2007**, *63*, 04412.
12. Amalraj, A.; Raghunathan, R. *Tetrahedron* **2001**, *57*, 10293–10298.
13. Jayashankaran, J.; Rathnadurga, R. S.; Raghunathan, R. *Arkivoc* **2003**, *XI*, 32–39.
14. Subramaniyan, G.; Raghunathan, R. *Tetrahedron* **2000**, *57*, 2909.
15. *Spiro-compound* **4a**: IR (KBr): 1690, 1718 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.09 (s, 3H), 3.28 (d, 2H, J = 12.8 Hz), 3.53 (s, 3H), 4.56 (d, 2H, J = 12.4 Hz), 4.98 (t, 1H, J = 11.2 Hz), 7.17–7.77 (m, 14H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 34.72, 43.75, 55.70, 62.00, 71.47, 107.64, 120.14, 122.96, 124.63, 127.30, 128.53, 129.11, 129.79, 130.76, 137.13, 141.66, 154.62, 192.02, 206.31 ppm; EIMS *m/z*: 474.02 (M^+); CHN Anal. Calcd for $C_{31}H_{25}NO_4$: C, 78.30; H, 5.30; N, 2.95; O, 13.46. Found: C, 78.28; H, 5.44; N, 2.90; O, 13.38.
16. *Spiro-compound* **4b**: IR (KBr): 1690, 1716 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.13 (s, 3H), 2.18 (s, 3H), 2.23 (s, 3H), 3.16 (s, 3H), 3.33 (d, 2H, J = 12.4 Hz), 4.66 (d, 2H, J = 12.2 Hz), 4.98 (t, 1H, J = 11.3 Hz), 7.03–7.77 (m, 12H), ^{13}C NMR ($CDCl_3$/400 MHz): δ 34.78, 43.27, 55.94, 57.43, 61.56, 71.59, 107.64, 118.57, 121.36, 124.41, 127.34, 128.03, 129.20, 129.64, 130.47, 136.98, 141.69, 147.05, 192.04, 206.35 ppm; EIMS *m/z*: 503.21 (M^+); CHN Anal. Calcd for $C_{33}H_{29}NO_4$: C, 78.71; H, 5.80; N, 2.78; O, 12.71. Found: C, 78.65; H, 5.77; N, 2.88; O, 12.70.
17. *Spiro-compound* **4c**: IR (KBr): 1692, 1718 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 1.93 (s, 3H), 2.15 (s, 3H), 3.16 (s, 3H), 3.28 (d, 2H, J = 12.2 Hz), 4.66 (d, 2H, J = 12.1 Hz), 4.98 (t, 1H, J = 11.4 Hz), 7.17–7.78 (m, 13H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 20.53, 34.83, 43.62, 55.96, 57.29, 71.56, 74.51, 108.80, 122.14, 124.63, 127.39, 128.56, 129.07, 129.67, 141.75, 147.06, 155.91, 192.15, 206.25 ppm; EIMS *m/z*: 489.19 (M^+); CHN Anal. Calcd for $C_{32}H_{27}NO_4$: C, 78.51; H, 5.56; N, 2.86; O, 13.07. Found: C, 78.44; H, 5.52; N, 2.89; O, 13.15.
18. *Spiro-compound* **4d**: IR (KBr): 1687, 1714 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 1.30 (t, 3H, J = 6.6 Hz), 2.83 (s, 3H), 2.90 (s, 3H), 2.15 (s, 3H,) 3.34 (d, 2H, J = 12.4 Hz), 3.93 (q, 2H), 4.54 (d, 2H, J = 12.2 Hz), 4.86 (t, 1H, J = 11.6 Hz), 6.67–7.69 (m, 12H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 34.78, 44.55, 55.76, 56.85, 65.02, 72.65, 74.51, 108.77, 120.33, 126.93, 128.50, 129.44, 129.51, 136.50, 141.11, 155.91, 192.68, 206.36 ppm; EIMS *m/z*: 517.23 (M^+); CHN Anal. Calcd for $C_{34}H_{31}NO_4$: C, 78.89; H, 6.04; N, 2.71; O, 12.36. Found: C, 78.80; H, 6.12; N, 2.68; O, 12.40.
19. *Spiro-compound* **4e**: IR (KBr): 1687, 1715 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 1.47 (t, 3H, J = 6.4 Hz), 2.16 (s, 3H), 2.18 (s, 3H), 3.33 (d, 2H, J = 12.2 Hz), 3.73 (s, 3H), 4.08 (q, 2H), 4.67 (d, 2H, J = 12.2 Hz), 4.98 (t, 1H, J = 11.4 Hz), 6.84–7.84 (m, 12H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 34.71, 43.06, 55.23, 57.87, 61.44, 64.69, 71.80, 113.84, 120.18, 120.23, 122.88, 124.35, 127.28, 128.44, 129.68, 130.56, 136.98, 141.70, 146.33, 158.78, 192.42, 206.38 ppm; EIMS *m/z*: 533.22 (M^+); CHN Anal. Calcd for $C_{34}H_{31}NO_5$: C, 76.53; H, 5.86; N, 2.62; O, 14.99. Found: C, 76.58; H, 5.84; N, 2.57; O, 14.92.
20. *Spiro-compound* **4f**: IR (KBr): 1690, 1714 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.70 (s, 3H), 3.20 (s, 3H) 3.37 (s, 3H), 3.38 (d, 2H, J = 12.2 Hz), 3.63 (d, 3H, J=6.0 Hz), 3.98 (d, 1H, J = 4.4 Hz), 4.68 (d, 2H, J = 12.4 Hz), 4.98 (t, 1H, J = 11.2 Hz), 5.88 (s, 1H), 6.75–7.54 (m, 12H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 34.78, 43.27, 55.94, 57.43, 61.56, 71.59, 107.64, 117.58, 118.57, 121.36, 124.41, 127.34, 128.03, 129.20, 129.64, 130.47, 136.98, 141.69, 147.05, 192.04, 206.35 ppm; EIMS *m/z*: 545.22 (M^+); CHN Anal. Calcd for $C_{35}H_{31}NO_5$: C, 77.04; H, 5.73;N, 2.57; O, 14.66. Found: C, 77.12; H, 5.75; N, 2.50; O, 14.63.
21. *Spiro-compound* **4g**: IR (KBr): 1690, 1718 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.20 (s, 3H), 2.74 (s, 3H), 3.36 (d, 2H, J = 11.8 Hz), 3.73 (s, 3H), 4.56 (d, 2H, J = 12.4 Hz), 4.98 (t, 1H, J = 11.3 Hz), 7.17–7.77 (m, 13H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 20.53, 34.83, 43.62, 55.96, 57.29, 71.56, 74.51, 108.80, 117.63, 122.14, 124.63, 127.39, 128.56, 129.07, 129.67, 141.75, 147.06, 155.91, 192.15, 206.25 ppm; EIMS *m/z*: 489.19 (M^+); CHN Anal. Calcd for $C_{32}H_{27}NO_4$: C, 78.51; H, 5.56; N, 2.86; O, 13.07. Found: C, 78.45; H, 5.65; N, 2.75; O, 13.15.
22. *Spiro-compound* **7a**: IR (KBr): 1690, 1710 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.62 (m, 4H), 3.32 (q, 1H), 3.41 (t, 2H, J = 12.2 Hz), 3.61 (s, 3H), 4.63 (d, 2H, J = 12.4 Hz), 4.87 (d, 1H, J = 6.0 Hz), 6.06–7.91δ (m, 14H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 25.34, 28.03, 29.65, 47.50, 48.14, 50.98, 55.65, 55.79, 60.75, 66.70, 67.57, 71.65, 107.73, 121.36, 123.54, 125.28, 127.81, 128.32, 129.27, 130.40, 131.47, 137.23, 141.67, 162.94, 194.35, 205.55 ppm; EIMS *m/z*: 500.18 (M^+); CHN Anal. Calcd for $C_{33}H_{27}NO_4$: C, 79.02; H, 5.43; N, 2.79; O, 12.76. Found: C, 79.05; H, 5.50; N, 2.72; O, 12.73.
23. *Spiro-compound* **7b**: IR (KBr): 1660, 1716 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.08 (s, 3H), 2.58 (m, 4H), 3.38 (q, 1H), 3.48 (t, 2H, J = 12.1 Hz), 3.83 (s, 3H), 4.63 (d, 2H, J = 12 Hz), 4.98 (d, 1H, J = 6.6 Hz), 6.27–7.99 (m, 13H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 25.04, 27.98, 48.35, 50.33, 56.19, 67.05, 71.99, 114.00, 118.39, 121.61, 124.40, 127.27, 127.53, 129.82, 130.05, 130.15, 141.32, 147.27, 158.87, 193.39, 206.25 ppm; EIMS *m/z*: 515.21 (M^+); CHN Anal. Calcd for $C_{34}H_{29}NO_4$: C, 79.20; H, 5.67; N, 2.72; O, 12.41. Found: C, 79.15; H, 5.62; N, 2.77; O, 12.45.
24. *Spiro-compound* **7c**: IR (KBr): 1665, 1714 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.41 (s, 3H), 2.66 (m, 4H), 3.30 (s, 3H), 3.38 (q, 1H), 3.54 (t, 2H, J=12.2 Hz), 3.61 (s, 3H), 4.70 (d, 1H, J = 6.4 Hz), 4.74 (d, 2H, J = 12.3 Hz), 6.90–7.69 (m, 12H); ^{13}C NMR ($CDCl_3$/ 400 MHz): δ 25.07, 27.97, 48.29, 50.66, 56.15, 66.90, 71.96, 114.00, 118.33, 121.59, 124.40, 127.27, 127.50, 129.01, 130.02, 130.55, 132.00, 141.29, 147.24, 148.61, 193.33, 206.14 ppm; EIMS *m/z*: 545.62 (M^+); CHN Anal. Calcd for $C_{35}H_{31}NO_5$: C, 77.04; H, 5.73; N, 2.57; O, 14.66. Found: C, 77.10; H, 5.67; N, 2.64; O, 14.59.
25. *Spiro-compound* **7d**: IR (KBr): 1669, 1713 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.36 (s, 3H), 2.65 (m, 4H), 2.78 (s, 3H), 3.40 (q, 1H), 3.67 (s, 3H), 3.75 (t, 2H, J = 12.3 Hz), 4.68 (d, 2H, J = 12.4 Hz), 4.80 (d, 1H, J = 6.6 Hz), 6.35–7.88 (m, 12H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 24.45, 28.05, 39.37, 48.29, 50.48, 56.23, 66.65, 71.96, 72.46, 114.76, 118.11, 121.36, 123.54, 127.28, 127.81, 128.32, 129.27, 130.40, 131.47, 137.23, 147.67, 148.94, 193.54, 206.45 ppm; EIMS *m/z*: 529.62 (M^+); CHN Anal. Calcd for $C_{35}H_{31}NO_4$: C, 79.37; H, 5.90; N, 2.64; O, 12.08. Found: C, 79.36; H, 5.85; N, 2.70; O, 12.01.
26. *Spiro-compound* **7e**: IR (KBr): 1668, 1711 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 1.40 (t, 3H, J = 5.6 Hz), 2.68 (m, 4H), 3.31 (s, 3H), 3.36 (q, 1H), 3.61 (s, 3H), 3.78 (t, 2H, J = 12.2 Hz), 4.02 (q, 2H), 4.53 (d, 2H, J = 12.2 Hz), 4.83 (d, 1H, J = 6.4 Hz), 6.77–7.88 (m, 12H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 20.50, 27.91, 39.37, 48.67, 50.40, 55.21, 67.14, 72.09, 114.20, 118.57, 120.92, 122.02, 124.48, 127.27, 128.42, 128.95, 130.20, 131.93, 137.15, 141.40, 146.47, 162.94, 192.94, 206.28 ppm; EIMS *m/z*: 575.65 (M^+); CHN Anal. Calcd for $C_{36}H_{33}NO_6$: C, 75.11; H, 5.78; N, 2.43; O, 16.68. Found: C, 75.05; H, 5.80; N, 2.42; O, 16.70.
27. *Spiro-compound* **7f**: IR (KBr): 1664, 1712 cm^{-1}; ^1H NMR ($CDCl_3$/400 MHz): δ 2.63 (m, 4H), 2.66 (s, 3H), 3.38 (q, 1H), 3.70 (s, 3H), 3.88 (t, 2H, J = 12.6 Hz), 4.55 (d, 2H, J = 12.2 Hz), 4.85 (d, 1H, J = 6.3 Hz), 6.25–7.99 (m, 13H); ^{13}C NMR ($CDCl_3$/400 MHz): δ 25.34, 28.03, 29.65, 48.14, 50.98, 55.65, 55.79, 60.75, 66.70, 67.57, 71.65, 107.73, 115.11, 121.36, 123.54, 125.28, 127.81, 128.32, 129.27, 130.40, 131.47, 137.23, 141.67, 162.94, 194.35, 205.55 ppm; EIMS *m/z*: 515.60 (M^+); CHN Anal. Calcd for $C_{34}H_{29}NO_4$: C, 79.20; H, 5.67; N, 2.72; O, 12.41. Found: C, 79.12; H, 5.60; N, 2.82; O, 12.51.